Kazia Therapeutics’ paxalisib reduced tumor burden by 52% in a preclinical MSS/pMMR colorectal cancer model, while combining it with immunotherapy reduced tumor Volume an additional 50%. The findings matter because Kazia plans a Phase 2 study, with enrollment expected to begin in the first quarter of 2027.
Key Highlights
- Kazia Therapeutics reported that paxalisib reduced tumor burden by 52% in a preclinical MSS/pMMR colorectal cancer model.
- It reports preclinical efficacy, tolerability, biomarker work, and a Patent filing, while noting that its ADSs trade under KZIA.
- And Share Registration The combination result carried a p-value of 0.022.
KAZIA THERAPEUTICS LTD (NASDAQ: KZIA) said paxalisib reduced total tumor burden by 52% in a preclinical model of MSS/pMMR colorectal cancer, with a result of p=0.035. A separate experiment found that adding the drug to immunotherapy cut tumor volume an additional 50% versus immunotherapy alone, while treatment was well tolerated in both studies.
Paxalisib Data
and Share Registration The combination result carried a p-value of 0.022. Kazia is developing a biomarker program to identify patients most likely to respond, measure early biological changes and support biomarker-led clinical development in pMMR colorectal cancer. Emerging biomarker findings and the preclinical results have also been incorporated into a new patent filing covering potential uses of paxalisib in colorectal cancer. Kazia’s ADSs trade on the Nasdaq Capital Market under the symbol KZIA.
FAQs
Q: What did Kazia Therapeutics report about paxalisib in colorectal cancer?
A: Kazia Therapeutics reported that paxalisib reduced tumor burden by 52% in a preclinical MSS/pMMR colorectal cancer model. Adding immunotherapy produced a further tumor-volume reduction.
Q: What is the potential stock impact of Kazia’s paxalisib data?
A: It reports preclinical efficacy, tolerability, biomarker work, and a patent filing, while noting that its ADSs trade under KZIA.
Q: When will Kazia Therapeutics begin its Phase 2 colorectal cancer trial?
A: The article does not state when Kazia Therapeutics will begin enrollment in a colorectal cancer trial.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.